Literature DB >> 3099048

Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil.

N D Nigro, A W Bull, M E Boyd.   

Abstract

An inhibitor of ornithine decarboxylase, difluoromethylornithine (DFMO), and two inhibitors of prostaglandin biosynthesis, piroxicam and menhaden fish oil, were examined for their effect on intestinal tumorigenesis in male Sprague-Dawley rats fed a 5% fat semisynthetic diet. Each agent was given individually in one of two doses as follows: DFMO, 0.05% and 0.1% in the drinking water; piroxicam, 65 mg/kg diet and 130 mg/kg diet; and menhaden fish oil, 1.25% and 2.50% of the diet. Additional animal groups were given combinations of the lower dose of DFMO and the lower dose of either piroxicam or fish oil. Intestinal tumors were induced by sc injections of azoxymethane (AOM; CAS: 25843-45-2) at 8 mg/kg (body wt) weekly for 8 weeks. Test diets were started 1 week prior to the first dose of AOM, and the rats were sacrificed 26 weeks later. Rats that received either dose of DFMO or the high dose of piroxicam developed significantly fewer intestinal tumors compared to controls. The low dose of piroxicam and the fish oil given at either dose level had no effect. The combination of the low dose of DFMO and the low dose of piroxicam reduced tumor formation more than either dose of DFMO alone, whereas the low dose of DFMO and fish oil together was no more effective than either dose of DFMO alone. These results show that a combination of a small amount of DFMO and piroxicam, each acting through a different mechanism, exerts an additive inhibitory effect on intestinal tumor formation in rats.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3099048

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  25 in total

Review 1.  Chemoprevention in familial adenomatous polyposis.

Authors:  Brian Kim; Francis M Giardiello
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-08       Impact factor: 3.043

2.  Cyclooxygenase-2: a potential target in human cancer.

Authors:  Jong-Ho Won
Journal:  Cancer Res Treat       Date:  2004-06-30       Impact factor: 4.679

Review 3.  Molecular targets for cancer chemoprevention.

Authors:  William N William; John V Heymach; Edward S Kim; Scott M Lippman
Journal:  Nat Rev Drug Discov       Date:  2009-03       Impact factor: 84.694

4.  Cloning and expression of ornithine decarboxylase gene from human colorectal carcinoma.

Authors:  Hai-Yan Hu; Xian-Xi Liu; Chun-Ying Jiang; Yan Zhang; Ji-Feng Bian; Yi Lu; Zhao Geng; Shi-Lian Liu; Chuan-Hua Liu; Xiao-Ming Wang; Wei Wang
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

5.  Antioxidant properties of aspirin: characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation, DNA damage, NF-kappaB activation, and TNF-alpha production.

Authors:  X Shi; M Ding; Z Dong; F Chen; J Ye; S Wang; S S Leonard; V Castranova; V Vallyathan
Journal:  Mol Cell Biochem       Date:  1999-09       Impact factor: 3.396

Review 6.  Aspirin, NSAIDs, and digestive tract cancers.

Authors:  M J Thun
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

Review 7.  Cancer pharmacoprevention: Targeting polyamine metabolism to manage risk factors for colon cancer.

Authors:  Eugene W Gerner; Elizabeth Bruckheimer; Alfred Cohen
Journal:  J Biol Chem       Date:  2018-10-24       Impact factor: 5.157

Review 8.  Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation.

Authors:  Eugene W Gerner; Frank L Meyskens
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

9.  Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.

Authors:  Christine E McLaren; Sharon Fujikawa-Brooks; Wen-Pin Chen; Daniel L Gillen; Daniel Pelot; Eugene W Gerner; Frank L Meyskens
Journal:  Cancer Prev Res (Phila)       Date:  2008-12

10.  Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.

Authors:  Frank L Meyskens; Christine E McLaren; Daniel Pelot; Sharon Fujikawa-Brooks; Philip M Carpenter; Ernest Hawk; Gary Kelloff; Michael J Lawson; Jayashri Kidao; John McCracken; C Gregory Albers; Dennis J Ahnen; D Kim Turgeon; Steven Goldschmid; Peter Lance; Curt H Hagedorn; Daniel L Gillen; Eugene W Gerner
Journal:  Cancer Prev Res (Phila)       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.